Fut, nem toboroz1/2. fázis
A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects with Gaucher Disease (GALILEO-2)
Key facts
- Where
- Zaragoza, SpanyolországSee the site
- Phase
- 1/2. fázis
Where in Spanyolország
- Hospital QuirónSalud ZaragozaZaragoza, SpanyolországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Spur Therapeutics Limited
- Trial code
- EU 2024-511172-33-00
- Record updated
- 2026. május 5.
- Original description
To assess the long-term safety of FLT201 in participants with Gaucher disease type 1.Read full original descriptionShow less
To assess the long-term safety of FLT201 in participants with Gaucher disease type 1.
Inclusion: Participants who have previously received FLT201 (including those who may have required recommencement or initiation of ERT/substrate reduction therapy [SRT]); Participants able to give full informed consent and able to comply with all requirements of the trial.
Exclusion: Not applicable.